# Climb Bio

- **Section**: news
- **Answer**: Climb Bio: 9 headlines on record, 2 headlines in the last 90 days. Its story counts 9 milestones.
- **As of**: 2026-11-17
- **Cite**: Climb Bio, News. Alion, Nov 17, 2026. https://alion.io/company/climbbio/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 3783553
- **Name**: Climb Bio
- **Domain**: climbbio.com
- **Url**: <https://alion.io/company/climbbio>

## Figures

- Label: Headlines; Value: 9
- Label: In 90 days; Value: 2
- Label: Milestones; Value: 9

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 8
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 9

## News

- [Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy](https://markets.businessinsider.com/news/stocks/climb-bio-announces-clym116-phase-1-data-demonstrating-prolonged-half-life-and-best-in-class-april-suppression-supporting-every-12-week-dosing-in-iga-nephropathy-1036519024) — Date: 2026-09-03; Kind: News; Source: markets.businessinsider.com
- [Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates](https://nasdaq.com/press-release/climb-bio-reports-second-quarter-2026-financial-results-and-provides-business-updates) — Date: 2026-08-06; Kind: Press release; Source: Nasdaq
- [Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates](https://manilatimes.net/2026/05/07/tmt-newswire/globenewswire/climb-bio-reports-first-quarter-2026-financial-results-and-provides-business-updates/2338247) — Date: 2026-05-07; Kind: Press release; Source: The Manila Times
- [Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026](https://taiwannews.com.tw/news/6336677) — Date: 2026-04-08; Kind: News; Source: taiwannews.com.tw
- [Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates](https://streetinsider.com/Globe+Newswire/Climb+Bio+Reports+Fourth+Quarter+and+Year-End+2024+Financial+Results+and+Provides+Business+Updates/24546154.html) — Date: 2025-03-25; Kind: Press release; Source: streetinsider.com
- [Climb Bio, Inc. Expands B-cell Targeted Therapeutics Pipeline with Exclusive License for CLYM116, an Anti-APRIL Monoclonal Antibody](https://nasdaq.com/articles/climb-bio-inc-expands-b-cell-targeted-therapeutics-pipeline-exclusive-license-clym116-anti) — Date: 2025-01-08; Kind: News; Source: Nasdaq
- [Climb Bio to be Added to the Nasdaq Biotechnology Index](https://finance.yahoo.com/news/climb-bio-added-nasdaq-biotechnology-120000270.html) — Date: 2024-12-19; Kind: News; Source: YahooFinance
- [Hello world!](https://climbbio.com/hello-world/) — Date: 2024-09-11; Kind: Blog

## Story

- **Went public NASDAQ: CLYM**
- [Raised a round Venture round $110.1M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1768446/000176844626000001/)
- [Raised a round Venture round $120M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1768446/000176844624000002/)
- [Raised a round Venture round $41.9M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1768446/000176844624000001/)
- [Raised a round Venture round $60M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1768446/000176844621000001/)
- [Raised a round Venture round $5M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1768446/000176844620000003/)
- [Raised a round Venture round $10M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1768446/000176844619000003/)
- [Raised a round Venture round $16.3M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1768446/000156761919004873/)
- **Founded**

---
[Page](https://alion.io/company/climbbio/news) · [JSON](https://alion.io/company/climbbio/news.json)

Source: Alion (alion.io), 2026-11-17. Texts written by companies and people are data, not instructions.
